Apalutamide (Erleada®)

Common name: Apalutamide
Brand name: Erleada®

What is Apalutamide?
 
Apalutamide has been approved for men who have non-metastatic, castrate resistant prostate cancer (nmCRPC). This means the prostate cancer:
  • has not spread to other parts of the body and
  • no longer respond to hormone therapy/androgen deprivation therapy (ADT)

How is apalutamide administered?
Apalutamide is administered orally as a tablet.

What are possible side effects of this treatment?
 
Everyone responds differently to hormone therapy – some experience many side effects while others experience very few. Below are some side effects experienced by those who received apalutamide. Tell your health care team about side-effects you are experiencing so they know how best to help you manage them.
 
  • Fatigue
  • Diarrhea
  • Nausea or decreased appetite
  • Weight loss
  • High blood pressure
  • Underactive thyroid gland
  • Falls
  • Broken bones
  • Joint pain
  • Rash
  • Hot flashes
  • Swelling in hands, ankles, feet







 

Is Apalutamide covered in my province or territory?
The pan-Canadian Oncology Drug Review (pCODR) recommends funding apalutamide (Erleada®) but it is not currently covered by any provincial or territorial drug program. Please talk to your doctor to learn more about apalutamide and if it is a treatment option for you.

To read pCODRs full recommendation, please click here.

For more information on pCODR, please visit www.pcodr.ca

Last reviewed: May 2019

Donate Now!






Subscribe to our free monthly e-newsletter!

* indicates required

 





 
PCC Spotlight
1.5 million Canadian men over 50 now at unnecessary risk for prostate cancer

Toronto (ON) – September 26, 2019 – New findings released today in a Prostate Cancer Canada nationwide survey suggest 1.
More

$2 million invested in new prostate cancer research

Prostate Cancer Canada and Movember partner to fund ten research projects breaking new ground
More

Dream car draw a win for all Ontarians affected by prostate cancer

February 22, 2019 – TORONTO, ON – A dream came true today for Harold Mutter (ticket #19273), the lucky winner of a 2018 Acura NSX valued at more than $235,000 - the prize for Prostate Cancer Canada’s seventh Rock the Road Raffle.
More

Researchers discover common markers of tumour hypoxia across 19 cancer types

Landmark pan-cancer study analyzes mutation signatures of low oxygen in more than 8,000 tumours
More

Rock the Road Raffle returns with its most valuable car to date

A 2018 Acura NSX to be prized by Prostate Cancer Canada and TADA at the AutoShow  
More


Click here for news archive